Business Wire

TX-FLUENCE-BY-OSRAM

23.11.2021 13:32:12 CET | Business Wire | Press release

Share
Fluence Partners with White Lion Holdings to Provide Crucial LED Lighting Solutions in Developing South African Commercial Cannabis Market

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it has partnered with White Lion Holdings , the leading consultant providing complete solutions for new and aspiring cannabis growers in South Africa.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211123005520/en/

Fluence’s South African partners include local distributor The Lamphouse, the largest supplier of specialized lamps in Africa with more than 40 years of experience in numerous specialty lighting sectors, and White Lion Holdings, a company offering complete cannabis growing solutions and consultancy, led by CEO Cornel van der Watt. Van der Watt has served at the forefront of developing cannabis markets in the U.S., Canada, the Netherlands and Lesotho, and has consulted extensively in Australia.

“Local partnerships are a key factor in delivering fast and reliable solutions to growers. Our stellar partners know the choice of lighting supplier is crucial to delivering consistent, high-quality yields premium clients in the northern hemisphere require,” said Timo Bongartz, Fluence’s general manager for Europe, the Middle East and Africa (EMEA). “Van der Watt chose to partner with Fluence and our local partner The Lamphouse based on his experience with Fluence’s superior LED products and valuable support in various jurisdictions where he has historically consulted cannabis growers.”

According to Prohibition Partners’ African Cannabis Report™ , by 2023, Africa’s legal cannabis industry could be worth more than $7.1 billion annually, with South Africa alone contributing an estimated $1.7 billion per year. The South African government’s recognition of the industry as a key to economic revival mirrors Prohibition Partners’ assessment—the cannabis industry represents the potential to create between 10,000 -25,000 job opportunities in a country with the highest unemployment rate in the world.

“The African cannabis market holds incredible potential and we know we’ve found the right partner in White Lion Holdings. We’re proud to collaborate with such a trusted brand and to support the growers who are revolutionizing the South African cannabis market,” Bongartz continues.

As the cannabis industry continues to gain traction throughout the country and continent, White Lion Holdings suggests growers will not only need innovative technology at their fingertips, but evidence-backed cultivation practices that yield high-quality crops, improved yields and consistent growth patterns.

“We’re thrilled to partner with Fluence and its local partner The Lamphouse,” said Van der Watt, who is currently consulting and managing four commercial operations throughout South Africa with other operations in the pipeline. “The cannabis plant is highly photosensitive. We prefer natural lighting and South Africa has an advantage in this regard with ample, good quality natural light. By choosing the location of the greenhouse well, one can get up to 11 hours of natural light for free. Then, we integrate supplemental lighting into the facility to optimize crop yield.”

The South African market is still in its infancy. Through its partnership with White Lion Holdings, Fluence lighting solutions have been implemented at pre-licensed and licensed cannabis greenhouse and indoor facilities throughout the country.

“I am testing various lighting solutions all the time, but those tests only reaffirm my partnership with Fluence and its local partner The Lamphouse given each company’s superior quality and valuable support. Thanks to consistent lighting, I have been able to surpass production targets. That is only possible with superior lighting,” Van der Watt added.

To achieve longevity in an industry that can quickly become crowded with new technologies and cultivation solutions, investors and growers must ensure they partner with experts in their respective fields who are purpose-built to support cultivators for the long-term.

“The Fluence system all but eliminates lighting as a variable and delivers a high return on investment. Optimizing the correct lighting strategy for the correct application and layout is one of the critical components to successful crop,” said Glenn Morris, CEO of The Lamphouse.

For more information on Fluence, visit www.fluence.science .

About Fluence by OSRAM

Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .

About Cornel van der Watt and White Lion Holdings

With over 29 years of international, large scale cannabis cultivation experience under his belt, the White Lion Cornel van der Watt is in a class of his own. His knowledge of all aspects of the cannabis industry and his connections in the global cannabis community are unparalleled. He has also been at the forefront of the cannabis movement in South Africa since inception.

Every path he has walked in his professional and personal life has led him back to the cannabis industry. This path traces back to his qualification in chemical engineering, experience in scientific glassblowing, expertise in cultivation abroad and locally, studies in tissue cultivation, cloning and genetics, his community upliftment work as well as training and consulting.

While Cornel has become a scientist, a geneticist, a businessman and Cannabis Supremo, at the heart of his consultancy lies a deep and spiritual connection with the cannabis plant. For more information about White Lion Holding, visit https://www.whitelionholdings.co.za .

About The Lamphouse

Established in 1976, The Lamphouse is the largest supplier and distributor of specialized lamps in Southern Africa. Over the past 40 years, The Lamphouse has developed strategic relationships with suppliers and customers alike, providing lighting applications for horticulture, medical solutions, stage and studio, airfield, navigation and more. The company is headquartered in Johannesburg, South Africa, with additional offices in Cape Town and Durban. For more information about The Lamphouse, visit https://www.thelamphouse.co.za .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye